Hrtwr Intrntl Inc (HTWR) 57.64 $HTWR
Medical Device Consolidation Frenzy: Here's How to Play it
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:00AM CDT
The medical device majors struggling with their core businesses are often on the lookout for emerging therapies through acquisitions and alliances.
ABT: 41.89 (+0.53), JNJ: 122.85 (+0.34), ZBH: 124.89 (+2.87), LDRH: 36.97 (-0.01), MDT: 88.36 (+0.87), TMO: 152.69 (+3.63), STJ: 80.58 (+0.43), HTWR: 57.64 (+0.11), XRAY: 63.39 (+0.89), NUVA: 60.82 (+1.11), FEIC: 106.78 (-0.23)
HeartWare International Has Returned 75.2% Since SmarTrend Recommendation (HTWR)
Comtex SmarTrend(R) - Wed Jul 06, 12:12AM CDT
SmarTrend identified an Uptrend for HeartWare International (NASDAQ:HTWR) on June 13th, 2016 at $32.77. In approximately 3 weeks, HeartWare International has returned 75.22% as of today's recent price of $57.42.
HTWR: 57.64 (+0.11)
Downgrade Alert for HeartWare International (HTWR)
Comtex SmarTrend(R) - Thu Jun 30, 3:01AM CDT
HeartWare International (NASDAQ:HTWR) was downgraded from Buy to Neutral at BTIG today. The stock closed yesterday at $57.46 on volume of 2.8 million shares, above average daily volume of 355,000. HeartWare International Inc is developing a range of implantable mechanical circulatory assist devices or heart pumps, used for the treatment of congestive heart failure.
HTWR: 57.64 (+0.11)
INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of HeartWare International, Inc. And Encourages Shareholders To Contact The Firm For Additional Information
BusinessWire - Tue Jun 28, 9:00PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of HeartWare International, Inc. (NASDAQ: HTWR) ("HeartWare" or the "Company"
relating to the proposed buyout of HeartWare by Medtronic plc.
MDT: 88.36 (+0.87), HTWR: 57.64 (+0.11)
Company News for June 28, 2016
Zacks Equity Research - Zacks Investment Research - Tue Jun 28, 9:10AM CDT
Companies In the News are: HTWR,MDT,SCNB,PBCT,SKUL,SPI
PBCT: 14.83 (+0.18), SKUL: 6.07 (+0.11), SPI: 5.97 (+0.02), MDT: 88.36 (+0.87), SCNB: 31.80 (+0.44), HTWR: 57.64 (+0.11)
Medtronic to Boost Heart Failure Business with HeartWare Buy
Zacks Equity Research - Zacks Investment Research - Tue Jun 28, 7:11AM CDT
Medtronic (MDT) recently entered into a merger agreement with Heartware International for the treatment of advanced heart failure.
ICUI: 115.00 (+1.34), MDT: 88.36 (+0.87), LMAT: 13.70 (+0.14), HTWR: 57.64 (+0.11)
Harwood Feffer LLP Announces Investigation of HeartWare International, Inc.
PR Newswire - Mon Jun 27, 1:41PM CDT
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of HeartWare International, Inc. ("HeartWare" or the "Company" (NASDAQ: HTWR) concerning the proposed acquisition of the Company by Medtronic, Inc. ("Medtronic".
MDT: 88.36 (+0.87), HTWR: 57.64 (+0.11)
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of HeartWare International, Inc. And Encourages Investors To Contact The Firm For Additional Information
BusinessWire - Mon Jun 27, 12:47PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of HeartWare International, Inc. (NASDAQ: HTWR) ("HeartWare" or the "Company" relating to the proposed buyout of HeartWare by Medtronic plc.
MDT: 88.36 (+0.87), HTWR: 57.64 (+0.11)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into the Fairness of the Sale of HeartWare International, Inc. to Medtronic plc for $58 Per Share - HTWR
ACCESSWIRE - Mon Jun 27, 11:51AM CDT
NEW YORK, NY / ACCESSWIRE / June 27, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
MDT: 88.36 (+0.87), HTWR: 57.64 (+0.11)
HeartWare Presentation At The Goldman Sachs 37th Annual Global Healthcare Conference To Be Webcast
PR Newswire - Wed Jun 01, 3:00PM CDT
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that members of HeartWare's executive management are scheduled to participate in a webcast session at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016 at 10:40 a.m. PT (1:40 p.m. ET). The conference is being held June 7-9 in Rancho Palos Verdes, California.
HTWR: 57.64 (+0.11)
HeartWare International Shares Down 16.8% Since SmarTrend's Sell Call (HTWR)
Comtex SmarTrend(R) - Fri May 20, 1:51PM CDT
SmarTrend identified a Downtrend for HeartWare International (NASDAQ:HTWR) on February 11th, 2016 at $33.69. In approximately 3 months, HeartWare International has returned 16.84% as of today's recent price of $28.01.
HTWR: 57.64 (+0.11)
HeartWare International Has Returned 19.9% Since SmarTrend Recommendation (HTWR)
Comtex SmarTrend(R) - Fri May 13, 1:03AM CDT
SmarTrend identified a Downtrend for HeartWare International (NASDAQ:HTWR) on February 11th, 2016 at $33.69. In approximately 3 months, HeartWare International has returned 19.86% as of today's recent price of $27.00.
HTWR: 57.64 (+0.11)
HeartWare Presentation At The Bank Of America Merrill Lynch 2016 Health Care Conference To Be Webcast
PR Newswire - Thu May 05, 3:15PM CDT
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that President and Chief Executive Officer Doug Godshall is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 10, 2016 at 4:20 p.m. PT (7:20 p.m. ET). The conference is being held May 10-12 in Las Vegas.
HTWR: 57.64 (+0.11)
Why Heartware International's Shares Are Sinking 12% Today
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 11:17AM CDT
SOURCE: HEARTWARE INTERNATIONAL, INC. What: After reporting first-quarter financial results that fell shy of industry watchers' forecasts, shares of Heartware International were tumbling by 12.4% at 11:30 a.m. EST. So what: The maker of...
HTWR: 57.64 (+0.11)
HeartWare International Reports First Quarter 2016 Financial Results
PR Newswire - Wed May 04, 6:00AM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue derived from HeartWare® Ventricular Assist System (HVAD® System) sales of $55.1 million for the first quarter ended March 31, 2016, compared to $70.0 million in revenue for the same period in 2015.
HTWR: 57.64 (+0.11)
HeartWare Completes Enrollment In HVAD® System LATERAL Study(TM)
PR Newswire - Wed Apr 27, 3:00PM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced completion of enrollment in the HeartWare® Ventricular Assist System (HVAD® System) LATERAL Study(TM).
HTWR: 57.64 (+0.11)
HeartWare Announces HVAD® System Scientific Presentations At The International Society For Heart And Lung Transplantation 36th Annual Meeting
PR Newswire - Wed Apr 20, 8:00AM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced a series of scientific presentations, highlighting the clinical and commercial use of the HVAD® System, at the International Society for Heart and Lung Transplantation (ISHLT) 36th Annual Meeting and Scientific Sessions to be held at the Marriott Wardman Park Hotel in Washington, D.C. on April 27-30, 2016.
HTWR: 57.64 (+0.11)
HeartWare Schedules First Quarter 2016 Financial Results Conference Call And Webcast
PR Newswire - Tue Apr 19, 3:00PM CDT
HeartWare International, Inc. (NASDAQ:HTWR) has scheduled a conference call and webcast to discuss its financial results for the three months ended March 31, 2016, on Wednesday, May 4, 2016 at 8:00 a.m. ET. The company plans to release the financial results prior to the conference call and webcast, during which management will discuss the company's financial results, highlights from the first quarter and business outlook.
HTWR: 57.64 (+0.11)
Ventricular Assist Device Market Analysis - Key Players are Abiomed, HeartWare International & Berlin Heart - Research and Markets
BusinessWire - Wed Mar 30, 7:37AM CDT
Research and Markets has announced the addition of the "Ventricular Assist Device Market Analysis by Product (Left, Right, Bi- Ventricular Assist Devices), and Segment Forecasts To 2022" report to their offering.
HTWR: 57.64 (+0.11)
March 22 Deadline Alert: Law Offices of Howard G. Smith Reminds HeartWare International, Inc. Investors of Upcoming Lead Plaintiff Deadline
BusinessWire - Mon Mar 21, 10:56AM CDT
Law Offices of Howard G. Smith reminds investors of the upcoming March 22, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased HeartWare International, Inc. ("HeartWare" or the "Company" (Nasdaq: HTWR) securities between June 10, 2014 and January 11, 2016, inclusive (the "Class Period". Investors who suffered losses on their investment in HeartWare securities are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights.
HTWR: 57.64 (+0.11)
Medical Device Consolidation Frenzy: Here's How to Play it
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:00AM CDT
The medical device majors struggling with their core businesses are often on the lookout for emerging therapies through acquisitions and alliances.
ABT: 41.89 (+0.53), JNJ: 122.85 (+0.34), ZBH: 124.89 (+2.87), LDRH: 36.97 (-0.01), MDT: 88.36 (+0.87), TMO: 152.69 (+3.63), STJ: 80.58 (+0.43), HTWR: 57.64 (+0.11), XRAY: 63.39 (+0.89), NUVA: 60.82 (+1.11), FEIC: 106.78 (-0.23)
HeartWare International Has Returned 75.2% Since SmarTrend Recommendation (HTWR)
Comtex SmarTrend(R) - Wed Jul 06, 12:12AM CDT
SmarTrend identified an Uptrend for HeartWare International (NASDAQ:HTWR) on June 13th, 2016 at $32.77. In approximately 3 weeks, HeartWare International has returned 75.22% as of today's recent price of $57.42.
HTWR: 57.64 (+0.11)
Downgrade Alert for HeartWare International (HTWR)
Comtex SmarTrend(R) - Thu Jun 30, 3:01AM CDT
HeartWare International (NASDAQ:HTWR) was downgraded from Buy to Neutral at BTIG today. The stock closed yesterday at $57.46 on volume of 2.8 million shares, above average daily volume of 355,000. HeartWare International Inc is developing a range of implantable mechanical circulatory assist devices or heart pumps, used for the treatment of congestive heart failure.
HTWR: 57.64 (+0.11)
INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of HeartWare International, Inc. And Encourages Shareholders To Contact The Firm For Additional Information
BusinessWire - Tue Jun 28, 9:00PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of HeartWare International, Inc. (NASDAQ: HTWR) ("HeartWare" or the "Company"
relating to the proposed buyout of HeartWare by Medtronic plc. MDT: 88.36 (+0.87), HTWR: 57.64 (+0.11)
Company News for June 28, 2016
Zacks Equity Research - Zacks Investment Research - Tue Jun 28, 9:10AM CDT
Companies In the News are: HTWR,MDT,SCNB,PBCT,SKUL,SPI
PBCT: 14.83 (+0.18), SKUL: 6.07 (+0.11), SPI: 5.97 (+0.02), MDT: 88.36 (+0.87), SCNB: 31.80 (+0.44), HTWR: 57.64 (+0.11)
Medtronic to Boost Heart Failure Business with HeartWare Buy
Zacks Equity Research - Zacks Investment Research - Tue Jun 28, 7:11AM CDT
Medtronic (MDT) recently entered into a merger agreement with Heartware International for the treatment of advanced heart failure.
ICUI: 115.00 (+1.34), MDT: 88.36 (+0.87), LMAT: 13.70 (+0.14), HTWR: 57.64 (+0.11)
Harwood Feffer LLP Announces Investigation of HeartWare International, Inc.
PR Newswire - Mon Jun 27, 1:41PM CDT
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of HeartWare International, Inc. ("HeartWare" or the "Company"
(NASDAQ: HTWR) concerning the proposed acquisition of the Company by Medtronic, Inc. ("Medtronic". MDT: 88.36 (+0.87), HTWR: 57.64 (+0.11)
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of HeartWare International, Inc. And Encourages Investors To Contact The Firm For Additional Information
BusinessWire - Mon Jun 27, 12:47PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of HeartWare International, Inc. (NASDAQ: HTWR) ("HeartWare" or the "Company"
relating to the proposed buyout of HeartWare by Medtronic plc. MDT: 88.36 (+0.87), HTWR: 57.64 (+0.11)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into the Fairness of the Sale of HeartWare International, Inc. to Medtronic plc for $58 Per Share - HTWR
ACCESSWIRE - Mon Jun 27, 11:51AM CDT
NEW YORK, NY / ACCESSWIRE / June 27, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
MDT: 88.36 (+0.87), HTWR: 57.64 (+0.11)
HeartWare Presentation At The Goldman Sachs 37th Annual Global Healthcare Conference To Be Webcast
PR Newswire - Wed Jun 01, 3:00PM CDT
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that members of HeartWare's executive management are scheduled to participate in a webcast session at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016 at 10:40 a.m. PT (1:40 p.m. ET). The conference is being held June 7-9 in Rancho Palos Verdes, California.
HTWR: 57.64 (+0.11)
HeartWare International Shares Down 16.8% Since SmarTrend's Sell Call (HTWR)
Comtex SmarTrend(R) - Fri May 20, 1:51PM CDT
SmarTrend identified a Downtrend for HeartWare International (NASDAQ:HTWR) on February 11th, 2016 at $33.69. In approximately 3 months, HeartWare International has returned 16.84% as of today's recent price of $28.01.
HTWR: 57.64 (+0.11)
HeartWare International Has Returned 19.9% Since SmarTrend Recommendation (HTWR)
Comtex SmarTrend(R) - Fri May 13, 1:03AM CDT
SmarTrend identified a Downtrend for HeartWare International (NASDAQ:HTWR) on February 11th, 2016 at $33.69. In approximately 3 months, HeartWare International has returned 19.86% as of today's recent price of $27.00.
HTWR: 57.64 (+0.11)
HeartWare Presentation At The Bank Of America Merrill Lynch 2016 Health Care Conference To Be Webcast
PR Newswire - Thu May 05, 3:15PM CDT
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that President and Chief Executive Officer Doug Godshall is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 10, 2016 at 4:20 p.m. PT (7:20 p.m. ET). The conference is being held May 10-12 in Las Vegas.
HTWR: 57.64 (+0.11)
Why Heartware International's Shares Are Sinking 12% Today
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 11:17AM CDT
SOURCE: HEARTWARE INTERNATIONAL, INC. What: After reporting first-quarter financial results that fell shy of industry watchers' forecasts, shares of Heartware International were tumbling by 12.4% at 11:30 a.m. EST. So what: The maker of...
HTWR: 57.64 (+0.11)
HeartWare International Reports First Quarter 2016 Financial Results
PR Newswire - Wed May 04, 6:00AM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue derived from HeartWare® Ventricular Assist System (HVAD® System) sales of $55.1 million for the first quarter ended March 31, 2016, compared to $70.0 million in revenue for the same period in 2015.
HTWR: 57.64 (+0.11)
HeartWare Completes Enrollment In HVAD® System LATERAL Study(TM)
PR Newswire - Wed Apr 27, 3:00PM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced completion of enrollment in the HeartWare® Ventricular Assist System (HVAD® System) LATERAL Study(TM).
HTWR: 57.64 (+0.11)
HeartWare Announces HVAD® System Scientific Presentations At The International Society For Heart And Lung Transplantation 36th Annual Meeting
PR Newswire - Wed Apr 20, 8:00AM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced a series of scientific presentations, highlighting the clinical and commercial use of the HVAD® System, at the International Society for Heart and Lung Transplantation (ISHLT) 36th Annual Meeting and Scientific Sessions to be held at the Marriott Wardman Park Hotel in Washington, D.C. on April 27-30, 2016.
HTWR: 57.64 (+0.11)
HeartWare Schedules First Quarter 2016 Financial Results Conference Call And Webcast
PR Newswire - Tue Apr 19, 3:00PM CDT
HeartWare International, Inc. (NASDAQ:HTWR) has scheduled a conference call and webcast to discuss its financial results for the three months ended March 31, 2016, on Wednesday, May 4, 2016 at 8:00 a.m. ET. The company plans to release the financial results prior to the conference call and webcast, during which management will discuss the company's financial results, highlights from the first quarter and business outlook.
HTWR: 57.64 (+0.11)
Ventricular Assist Device Market Analysis - Key Players are Abiomed, HeartWare International & Berlin Heart - Research and Markets
BusinessWire - Wed Mar 30, 7:37AM CDT
Research and Markets has announced the addition of the "Ventricular Assist Device Market Analysis by Product (Left, Right, Bi- Ventricular Assist Devices), and Segment Forecasts To 2022" report to their offering.
HTWR: 57.64 (+0.11)
March 22 Deadline Alert: Law Offices of Howard G. Smith Reminds HeartWare International, Inc. Investors of Upcoming Lead Plaintiff Deadline
BusinessWire - Mon Mar 21, 10:56AM CDT
Law Offices of Howard G. Smith reminds investors of the upcoming March 22, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased HeartWare International, Inc. ("HeartWare" or the "Company"
(Nasdaq: HTWR) securities between June 10, 2014 and January 11, 2016, inclusive (the "Class Period". Investors who suffered losses on their investment in HeartWare securities are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights. HTWR: 57.64 (+0.11)
